0000049071-25-000042
SEC filingRevenue grew 9.6% driven by higher Medicare premiums and state-based contracts, but net income fell 19.9% due to a higher benefit ratio.
For the three months ended June 30, 2025, total revenue rose 9.6% to $32.4 billion from $29.5 billion in the prior-year quarter. The increase was driven by a 9.1% rise in insurance premiums to $30.7 billion, reflecting higher per-member Medicare premiums (largely due to an increased direct subsidy from the Inflation Reduction Act) and growth in state-based contracts and stand-alone PDP businesses. Services revenue grew 27.3% to $1.4 billion, led by CenterWell's primary care and pharmacy solutions. Investment income declined 8.7% to $272 million due to lower interest income on debt securities.
Net income attributable to Humana decreased 19.9% to $543 million ($4.51 per diluted share) from $678 million ($5.62 per share) a year ago. The decline was primarily driven by a 70-basis-point increase in the consolidated benefit ratio to 89.7%, reflecting a shift in business mix toward higher-ratio lines (state-based contracts and stand-alone PDP) and incremental investments to improve member outcomes. Operating costs increased 12.7% to $3.5 billion, raising the operating cost ratio by 20 basis points to 11.0% due to business mix changes and operating leverage from individual Medicare Advantage membership losses, partially offset by cost efficiencies from value creation initiatives. Depreciation and amortization fell 16.0% to $178 million on reduced capital spending.
Pre-tax income was negatively impacted by $261 million in non-operational adjustments, including $200 million in put/call valuation adjustments, $32 million in impairment charges, and $29 million in value creation initiative costs. Excluding these items, adjusted pre-tax income would have been higher than the reported $741 million.
Insurance Segment: Premiums revenue increased 9.1% to $30.7 billion, with notable growth in stand-alone PDP (98.5% to $1.7 billion) and state-based contracts (37.1% to $3.5 billion), partially offset by a 6.9% decline in individual Medicare Advantage membership to 5.23 million. The Insurance benefit ratio rose 40 basis points to 89.9% due to mix shift and membership losses, while the operating cost ratio improved 10 basis points to 8.3% from administrative efficiencies. Segment income from operations was essentially flat at $766 million (up $3 million).
CenterWell Segment: External services revenue surged 34.8% to $1.2 billion, driven by primary care (+59.3% to $513 million) and pharmacy solutions (+40.2% to $321 million). Intersegment revenue grew 6.9% to $4.3 billion. The operating cost ratio increased 70 basis points to 92.7% due to the continued phase-in of the v28 risk model revision in primary care, partly offset by stabilizing medical cost trends and mitigation activities. Despite revenue growth, operating income rose just 1.8% to $344 million.
Management emphasized ongoing value creation initiatives expected to incur additional charges in 2025, including asset impairments and severance. The company highlighted the impact of the Inflation Reduction Act on Part D benefit design, which eliminates the coverage gap and caps member out-of-pocket costs at $2,000, leading to more level prescription costs throughout the year. Strategic priorities remain focused on integrated care delivery, with 68% of individual Medicare Advantage members in value-based arrangements (down from 70% a year ago). No specific numeric guidance was provided for future periods, but the exit from unprofitable plans and counties is expected to support margin improvement. Liquidity remains strong with $4.0 billion in cash and cash equivalents at June 30, 2025, and access to $1.5 billion in net proceeds from recent debt issuances.
As of June 30, 2025, Humana reported cash and cash equivalents of $4.8 billion, compared to $5.2 billion at December 31, 2024. Total debt was $12.1 billion, unchanged from year-end 2024. Shareholders' equity increased to $16.5 billion from $15.8 billion at December 31, 2024, reflecting net income and share repurchases.
The Notes to Financial Statements do not disclose any material purchase commitments or contractual obligations beyond routine operating lease and debt service obligations. No significant off-balance-sheet arrangements or long-term supply commitments were noted.
During the six months ended June 30, 2025, Humana repurchased $1.2 billion of its common stock. As of June 30, 2025, the company had $1.5 billion remaining under its share repurchase authorization. Dividends paid totaled $0.2 billion, with a quarterly dividend of $0.885 per share. No new debt issuance or repayment was reported. Capital expenditures were not separately disclosed in the Notes.
The Notes do not include segment-level financial data. Segment information is typically provided in the MD&A section, which is outside the scope of this analysis.
Operating cash flow (CFO) for the six months ended June 30, 2025 was $1.7 billion, a decrease of $0.3 billion from $2.0 billion in the prior year period. This decline occurred despite net income growth, indicating potential working capital headwinds or timing of receipts/payments. Capital expenditures (capex) increased to $0.4 billion from $0.3 billion, reflecting higher investment intensity. Free cash flow (CFO minus capex) was approximately $1.3 billion, down from $1.7 billion in the prior year. The company returned $0.3 billion to shareholders via share repurchases, a reduction from $0.5 billion in the prior year period, and paid no dividends. The financing cash flow of -$1.3 billion was primarily driven by share repurchases and debt repayments. No significant anomalies such as large one-time tax payments or major working capital swings were explicitly noted in the excerpt, but the CFO decline relative to net income warrants further investigation into changes in receivables, payables, and reserves.